Kadeerhan Gaohaer, Xue Bo, Wu Xiao-Lin, Chen Wei-Nan, Wang Dong-Wen
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Urology and Lithotripsy Center, Peking University People's Hospital, Beijing, China.
Front Oncol. 2023 Aug 3;13:1201753. doi: 10.3389/fonc.2023.1201753. eCollection 2023.
The incidence of prostate cancer (PCa) has continued to increase since the US Preventive Services Task Force (USPSTF) recommendations against prostate-specific antigen (PSA)-based screening for all men in 2012, approximately half of additional diagnosed cases are advanced-stage, including regional PCa and metastatic PCa (mPCa). It is very important to investigate the shift in mPCa incidence and mPCa-related mortality risk, as the survival of mPCa remains poor.
To investigate the incidence temporal trend of mPCa stratified by metastatic site, including bone and visceral metastatic involvement, and potential survival improvements.
Based on the recently released Surveillance, Epidemiology, and End Results (SEER) data (2010-2019), the age-adjusted incidence rates of mPCa with bone and visceral involvement with annual percentage changes (APCs) were assessed by a joinpoint regression model in men aged 45 years and older by age and race groups, and potential recent improvements in overall survival (OS) and cancer-specific survival (CSS) were estimated by the Kaplan-Meier method and Cox regression model.
From 2010 to 2019, a total of 19081 (84.8%) and 3413 (15.2%) mPCa patients with bone and visceral involvement, respectively, were recorded in the SEER database. Considering all races and age groups, the incidence rate of mPCa with bone metastasis remained stable during 2017-2019 (APC, 0.9%; =0.421) after increasing during 2010-2017 (APC, 5.8%; <0.001). For visceral metastasis, the incidence rate increased by 12.3% (<0.001) per year from 2010-2019. Non-Hispanic Black men have higher incidence rates than other populations, and the Non-Hispanic Black to Non-Hispanic White incidence rates ratios of mPCa declined with the greater increasing pace of incidence of Non-Hispanic White men. There was a slight improvement in both OS and CSS among men with bone and visceral metastasis involvement when comparing the 2013-2016 period to the pre-2013 period.
Our findings show that the incidence of mPCa with bone and visceral involvement has increased in recent years and that there has been a potential improvement in survival. Future efforts are still needed to watch closely if the rising incidence trends continue.
自美国预防服务工作组(USPSTF)于2012年建议反对对所有男性进行基于前列腺特异性抗原(PSA)的筛查以来,前列腺癌(PCa)的发病率持续上升,新增确诊病例中约一半为晚期,包括局部PCa和转移性PCa(mPCa)。由于mPCa的生存率仍然很低,因此研究mPCa发病率的变化以及与mPCa相关的死亡风险非常重要。
研究按转移部位分层的mPCa发病率的时间趋势,包括骨转移和内脏转移,并探讨潜在的生存改善情况。
基于最近发布的监测、流行病学和最终结果(SEER)数据(2010 - 2019年),采用Joinpoint回归模型评估45岁及以上男性按年龄和种族分组的骨转移和内脏转移mPCa的年龄调整发病率及年变化百分比(APC),并采用Kaplan - Meier方法和Cox回归模型估计总体生存(OS)和癌症特异性生存(CSS)的近期潜在改善情况。
2010年至2019年,SEER数据库中分别记录了19081例(84.8%)骨转移和3413例(15.2%)内脏转移的mPCa患者。考虑所有种族和年龄组,骨转移mPCa的发病率在2010 - 2017年上升(APC,5.8%;P<0.001)后,在2017 - 2019年保持稳定(APC,0.9%;P = 0.421)。对于内脏转移,2010 - 2019年发病率每年上升12.3%(P<0.001)。非西班牙裔黑人男性的发病率高于其他人群,且随着非西班牙裔白人男性发病率上升速度加快,非西班牙裔黑人与非西班牙裔白人mPCa发病率之比下降。与2013年前相比,2013 - 2016年期间骨转移和内脏转移男性的OS和CSS均有轻微改善。
我们的研究结果表明,近年来骨转移和内脏转移mPCa的发病率有所上升,且生存情况有潜在改善。如果发病率上升趋势持续,未来仍需密切关注。